Etoposide plus platinum (either cisplatin or carboplatin) as the standard first-line regimen for poorly-differentiated NECAs, and as we know this combination has been adopted from SCLC with limited data in extrapulmonary NECA. Both combinations are equally effective, however, the toxicity profile ma...